In reply: Covariate adjustment for prognostic baseline characteristics may decrease the sample size
Authors: Anthony C Keech and Val J Gebski
Published online: 7 April 2003
In reply: While we agree that covariate adjustment during analysis can be a potential mechanism for reducing sample size (even when there is no imbalance in the important covariate levels between the treatment groups), unless such analyses are prospectively planned then they will not allow valid statistical inference. This is because post-hoc adjustment is an exploratory procedure and may have involved examining any number of potential covariates.
Further, to quantify any anticipated sample-size gains would depend on specifying likely maximum covariate imbalances, overall covariate distributions and plausible effects of treatment within the covariate levels during study design. In practice, the study would then have to meet these assumptions for the calculated sample-size gain to be achieved.
Covariate adjustment is an accepted practice for subsidiary analysis in clinical trials, and can take account of differential effects in imbalanced subgroups. For example, see the case of an apparent chance imbalance in numbers of women in the treatment arms of the HERO-2 trial, where investigators presented both unadjusted and adjusted results.1
Where important predictors of the clinical outcomes are expected to be variable for the population under study, a particularly useful approach is to stratify the randomisation by those predictors.2 Such stratification allows for valid adjusted analyses.3
References
- The Hirulog and Early Reperfusion or Occlusion (HERO-2) Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001; 358: 1855-1863. ref2
- Keech AC, Gebski V. Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects? Med J Aust 2002; 177: 445-447. <eMJA full text>
- Gebski V, Keech AC. Statistical methods in clinical trials. Med J Aust 2003; 178: 182-184. <eMJA full text>
Interpreting Australian Stillbirth Rate Trends: Implications for Surveillance and Continuous Quality Improvement
Aleena M. Wojcieszek, Kirstine Sketcher-Baker, Christine Andrews, Michael Coory, Imogen Kettle, Melissa Malivoire, David Ellwood, Vicki Flenady
Paracetamol in Pregnancy: Uncertain Evidence, Certain Consequences
David J. Tunnicliffe, Miranda Cumpston, Debra Kennedy, Margie Danchin, Armando Teixeira-Pinto
Fatty Liver Disease in Australia: A Narrative Review on the Epidemiology, Natural History, Prognostication and Management in People With Metabolic Dysfunction
Karl Vaz, Daniel Clayton-Chubb, William W. Kemp, Stuart K. Roberts, Ammar Majeed
Birth prevalence, clinical sequelae, and management of congenital cytomegalovirus infections in Australia, 1999–2023: a national prospective study
Ece Egilmezer, Suzy M Teutsch, Carlos Nunez, Stuart T Hamilton, Adam W Bartlett, Pamela Palasanthiran, Elizabeth J Elliott, William D Rawlinson
The number of cancer‐related deaths that could be attributable to spatial disparities in survival in Australia, 2010–2019: a retrospective population‐based cohort study
Charlotte K Bainomugisa, Jessica Cameron, Paramita Dasgupta, Peter Baade
Mandatory research projects during medical specialist training in Australia and New Zealand
Paulina Stehlik, Caitlin Brandenburg, David A Henry